This site is intended for healthcare professionals
FDA Hero Banner - Multi-coloured pills and tablets
FDA Drug information

Betamethasone dipropionate

Read time: 1 mins
Marketing start date: 01 May 2024
...
 

Summary of product characteristics


Effective Time

20220803

Version

3

Spl Product Data Elements

Betamethasone dipropionate Betamethasone dipropionate BETAMETHASONE DIPROPIONATE BETAMETHASONE CETETH-20 CETOSTEARYL ALCOHOL CHLOROCRESOL MINERAL OIL PETROLATUM SODIUM PHOSPHATE, MONOBASIC WATER off white

Application Number

ANDA208885

Brand Name

Betamethasone dipropionate

Generic Name

Betamethasone dipropionate

Product Ndc

70771-1380

Product Type

HUMAN PRESCRIPTION DRUG

Route

TOPICAL

Package Label Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 70771-1380-1 Betamethasone dipropionate cream USP, 0.05% Rx only 15 g Betamethazone Dipropionate Cream, USP Betamethazone Dipropionate Cream, USP

Relevant Learning Zones

Psoriasis Academy
Plaque psoriasis

When it comes to psoriasis, a knowledgeable healthcare professional is highly valued by patients (Pariser et al., 2016). With this in mind, we created The Psoriasis Academy, an online hub featuring succinct and easily accessible information for all healthcare professionals who want to know more about psoriasis and keep up to date with the latest developments.
Improving treatment options for childhood psoriasis
Improving treatment options for child psoriasis banner image, child and doctor

This Learning Zone introduces you to our young patient Mia who, along with our paediatric psoriasis experts, helps us to describe the burden of childhood psoriasis for patients and their families, particularly the difficulties around diagnosis, comorbidities and limited treatment options.

Drug section

Plaque psoriasis
Plaque psoriasis
Learning Zone Homepage

Psoriasis Academy

When it comes to psoriasis, a knowledgeable healthcare professional is highly valued by patients (Pariser et al., 2016). With this in mind, we created The Psoriasis Academy, an online hub featuring succinct and easily accessible information for all healthcare professionals who want to know more about psoriasis and keep up to date with the latest developments.

Read more
910 mins
Learning Zone Homepage

Improving treatment options for childhood psoriasis

This Learning Zone introduces you to our young patient Mia who, along with our paediatric psoriasis experts, helps us to describe the burden of childhood psoriasis for patients and their families, particularly the difficulties around diagnosis, comorbidities and limited treatment options.

Read more
270 mins
CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.